Atopic Dermatitis

Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.

Adelaide A. Hebert, MD, FAAD, stressed the importance of educating patients, setting realistic expectations, and ensuring they adhere to AD treatment plans.

Alexandra Golant, MD, led a Dermatology Times Case-Based Roundtable® event that focused on advancing therapeutic strategies for atopic dermatitis.

Hawkes discusses urticaria subtypes, treatments, and emerging therapies like dupilumab and remibrutinib.

At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, presented a case of a woman aged 27 years who had eczematous lesions covering more than 20% of her BSA.

New drugs targeting IL-4, IL-13, and IL-31 pathways provide options for tailored eczema treatments.

Lisa Weiss, MMSc, PA-C, and colleagues offered insights on managing severe atopic dermatitis cases with biologics, nonsteroidal treatments, and strategies for addressing physical and emotional impacts.

A recent expert discussion highlighted the importance of long-term planning, including when and how to adjust or transition therapies.

Tina Bhutani-Jacques, MD, highlighted the importance of individualized and informative care while building trust among patients and caregivers.

Nektar Therapeutics’ investigational biologic targets the IL-2 receptor complex.

Many patients with severe AD are unaware of newer, more effective treatments.

His presentation at South Beach Symposium will feature Zirwas’ insights on JAK inhibitors, eczema treatments, and emerging therapies.

At the Horizons in Advanced Practice meeting, Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, presented a case of a woman aged 35 years with widespread eczematous lesions covering over 50% BSA and severe lichenification.

James Del Rosso, DO, explored the treatment landscape and the importance of regular eye exams for patients with AD.

A new review highlights overall allergen rates among children in the United States between 2010 and 2024.

Researchers analyzed stratum corneum hydration and transepidermal water loss across 15 regions of the skin.

According to a systemic review, both topical and oral antifungal therapies are insufficient for managing the disease.

The use of a pre-gel and cleansing lotion regimen saw an improvement rate of 80% for patients with seborrheic dermatitis.

Investigators found strong correlations between certain eating habits, BMI, psychoemotional status, and SD occurrence.

The new partnership will advance the commercialization of small molecule oral STAT6 for patients around the world.

A panelist discusses how health care providers can address patients’ concerns about topical treatment side effects in atopic dermatitis by providing education about proper application, expected outcomes, and the strong safety profile of modern topical medications.

A panelist discusses how the choice between systemic and topical treatments for atopic dermatitis patients should be based on factors like disease severity, affected body surface area, impact on quality of life, and previous treatment response.

Rezpegaldesleukin, a novel IL-2 receptor agonist, enters phase 2b evaluation for atopic dermatitis, aiming to advance therapeutic options for this chronic condition.

A study revealed ruxolitinib cream's rapid, lasting benefits in pediatric eczema without systemic safety concerns over a 52-week trial period.

Experts explore innovative therapies, psychosocial impacts, and education strategies for managing atopic dermatitis in a Dermatology Times video series.

More improved skin hydration and barrier function was observed in moisturizers with anti-inflammatory ingredients, compared to those without.

Real-world data from TARGET-DERM AD revealed that those with both reduced itch and clearer skin had the lowest levels of disease burden.

The panelist discusses how safety data from clinical trials and real-world evidence should guide physicians in prescribing ruxolitinib cream, including patient monitoring protocols and managing potential adverse effects in atopic dermatitis treatment.

The panelist discusses how to effectively communicate with patients about nonsteroidal topical treatment options for atopic dermatitis, including their benefits, proper application methods, and expected outcomes.

The panelist discusses how ruxolitinib treats atopic dermatitis by inhibiting Janus kinase (JAK)1/JAK2 signaling pathways to reduce inflammation and alleviate symptoms of the skin condition.